Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering i-lipiodol therapy for hepatocellular carcinoma

Nuclear Medicine Communications

Volumn 24, Issue 6, 2003, Pages 671-678

  Garin, E ^a   Laffont, S ^a   Rolland, Y ^a   OliviÉ, D ^a   Lecloirec, J ^a   Herry, J Y ^b   Boucher, E ^b   Raoul, J L ^b   Bourguet, P ^b  

^a Nucléaire Centre Eugène Marquis   (United States)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Internal radiotherapy; Liver; Radiation exposure

Indexed keywords

IODINATED POPPYSEED OIL; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL TRIAL; FILM DOSIMETER; FINGER; HEALTH CARE PERSONNEL; HUMAN; INSTRUMENTATION; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY; NUCLEAR MEDICINE; OCCUPATIONAL EXPOSURE; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RISK ASSESSMENT; THERMOLUMINESCENCE DOSIMETRY; THORAX;

CARCINOMA, HEPATOCELLULAR; FILM DOSIMETRY; FINGERS; HEALTH PERSONNEL; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; NUCLEAR MEDICINE; OCCUPATIONAL EXPOSURE; RADIATION DOSAGE; RADIATION INJURIES; RADIATION PROTECTION; RADIOPHARMACEUTICALS; RISK ASSESSMENT; THERMOLUMINESCENT DOSIMETRY; THORAX;

EID: 0842312160     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200306000-00009     Document Type: Article

References (35)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
2. Trinchet JC, Beaugrand M. Augmentation de l'incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 1999; 23: 1286-1288.
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1974-94. Lancet 1997; 350: 1142-1143.
4. Deuffic S, Poynard T. Trends in primary liver cancer. Lancet 1998; 351: 214-215.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999; 340: 745-750.
6. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32(suppl 1): 225-237.
7. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modelling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-1601.
8. Suarez Y, Sala M, Llovet JM, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 1999; LXII: 410-414.
9. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76: 4-11.
10. Bronowiki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74: 16-24.
11. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-2434.
12. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184.
13. Groupe d'étude et de traitement du carcinome hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New Engl J Med 1995; 332: 1256-1261.
14. 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156-1161.
15. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 1782-1787.
16. Lau WY, Leung TWT, Ho SKW, et al. Adjuvant intra-arterial iodine-131-labelled Lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353: 797-801.
17. Kobayashi H, Hidaka H, Kajiya Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diag 1986; 27: 139-147.
18. Park CH, Suh JH, Yoo HS, Lee JT, Kim DI, Kim BS. Treatment of hepatocellular carcinoma (HCC) with radiolabelled Lipiodol: a preliminary report. Nucl Med Comm 1987; 8: 1075-1087.
19. Bretagne JF, Raoul JL, Bourguet P, et al. Hepatic artery injection of I-131-labeled Lipiodol. Radiology 1988; 168: 547-550.
20. Yoo HS, Park CH, Suh JH, et al. Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. Cancer Chemother Pharmacol 1989; 23(suppl): S54-S58.
21. Lui WY, Liu RS, Chiang JH, et al. Report of a pilot study of intra-arterial injection of I-131 Lipiodol for the treatment of hepatoma. Chin Med J (Taipei) 1990; 46: 125-133.
22. Yoo HS, Lee JT, Kim KW, et al. Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 1991; 68: 1878-1884.
23. Raoul JL, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992; 69: 346-352.
24. Yumoto Y, Jinno K, Inatsuki S, et al. Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol 1992; 31(suppl.): S128-S136.
25. Kajiya Y, Kobayashi H, Nakajo M. Transarterial internal radiation therapy with I-131 lipiodol for multifocal hepatocellular carcinoma: intermediate and long term results. Cardiovasc Intervent Radiol 1993; 16: 150-157.
26. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35: 1313-1318.
27. Yoo HS, Park CH, Lee JT, et al. Small hepatocellular carcinoma: high dose internal radiation therapy with super-selective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 1994; 33(suppl): S128-S133.
28. 131Iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76: 2202-2210.
29. Maini CL, Scelsa MG, Fiumara C, et al. Superselective intra-arterial radiometabolic therapy with I-131 Lipiodol in hepatocellular carcinoma. Clin Nucl Med 1996; 21: 221-226.
30. 131I iodized oil for treatment of hepatocellular carcinoma in patient with impeded portal venous flow. Radiology 1999; 212: 665-668.
31. Partensky C, Sassolas G, Henry L, Paliar P, Maddern GJ. Intra-arterial iodine 131-labeled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 2000; 135: 1298-1300.
32. 131I-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 4: 333-338.
33. Risse JH, Ponath C, Palmedo H, Menzel C, Grünwald F, Biersack HJ. Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver cancer. Eur J Nucl Med 2001; 28: 914-918.
34. 131I-labeled Lipiodol. Part 1. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541-545.
35. Novel JR, Hilson AJW. Iodine-131-lipiodol for hepatocellular carcinoma: the benefit of targeting. J Nucl Med 1994; 35: 1318-1320.